Jacobio Pharmaceuticals Group's (HKG:1167) subsidiary Jacobio Pharmaceuticals received an upfront payment of 172.8 million yuan from Shanghai Allist Pharmaceuticals (SHA:688578) for the License-Out agreement between the parties, a Friday filing with the Hong Kong Exchange said.
The payment includes the upfront payment of 150 million yuan and partial payment for research and development expenses out of the total of 200 million yuan Jacobio is supposed to receive from Allist in the near term.
Jacobio Pharmaceuticals, the subsidiary, had entered into a license-out agreement for the R&D, manufacturing, and commercialization of its Glecirasib (JAB-21822) and JAB-3312 with Allist for the regions of China, Hong Kong, Macau, and Taiwan on Aug. 30.
The oncology therapies company's shares closed nearly 5% higher on Friday.
Price (HKD): $1.84, Change: $+0.080, Percent Change: +4.55%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。